Global Recombinant Human Erythropoietin (rhEPO) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Human Erythropoietin (rhEPO) Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
The process of supplying EPO externally, usually with the help of recombinant DNA technology in a cell culture, is known as rhEPO. rhEPO is used to treat anemia due to neural diseases, injuries, kidney diseases or cancer.
Recombinant Human Erythropoietin (rhEPO) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Human Erythropoietin (rhEPO) market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Hospitals and Retail Pharmacies are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Recombinant Human Erythropoietin (rhEPO) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Recombinant Human Erythropoietin (rhEPO) key manufacturers include 3SBio, Shanghai Chemo, Chengdu Diao, NCPC Genetech, Kyowa Hakko Kirin, Shandong Kexing, Ahua Pharmaceutical, Biosidus and Dragon Pharma, etc. 3SBio, Shanghai Chemo, Chengdu Diao are top 3 players and held % sales share in total in 2022.
Recombinant Human Erythropoietin (rhEPO) can be divided into ESRD, Cancer, HIV and Wounds and Neural Disease, etc. ESRD is the mainstream product in the market, accounting for % sales share globally in 2022.
Recombinant Human Erythropoietin (rhEPO) is widely used in various fields, such as Hospitals and Retail Pharmacies, etc. Hospitals provides greatest supports to the Recombinant Human Erythropoietin (rhEPO) industry development. In 2022, global % sales of Recombinant Human Erythropoietin (rhEPO) went into Hospitals filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Human Erythropoietin (rhEPO) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
3SBio
Shanghai Chemo
Chengdu Diao
NCPC Genetech
Kyowa Hakko Kirin
Shandong Kexing
Ahua Pharmaceutical
Biosidus
Dragon Pharma
Segment by Type
ESRD
Cancer
HIV
Wounds and Neural Disease
Hospitals
Retail Pharmacies
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Recombinant Human Erythropoietin (rhEPO) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Human Erythropoietin (rhEPO), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Human Erythropoietin (rhEPO) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Human Erythropoietin (rhEPO) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Human Erythropoietin (rhEPO) introduction, etc. Recombinant Human Erythropoietin (rhEPO) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Recombinant Human Erythropoietin (rhEPO) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Recombinant Human Erythropoietin (rhEPO) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Human Erythropoietin (rhEPO) market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Hospitals and Retail Pharmacies are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Recombinant Human Erythropoietin (rhEPO) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Recombinant Human Erythropoietin (rhEPO) key manufacturers include 3SBio, Shanghai Chemo, Chengdu Diao, NCPC Genetech, Kyowa Hakko Kirin, Shandong Kexing, Ahua Pharmaceutical, Biosidus and Dragon Pharma, etc. 3SBio, Shanghai Chemo, Chengdu Diao are top 3 players and held % sales share in total in 2022.
Recombinant Human Erythropoietin (rhEPO) can be divided into ESRD, Cancer, HIV and Wounds and Neural Disease, etc. ESRD is the mainstream product in the market, accounting for % sales share globally in 2022.
Recombinant Human Erythropoietin (rhEPO) is widely used in various fields, such as Hospitals and Retail Pharmacies, etc. Hospitals provides greatest supports to the Recombinant Human Erythropoietin (rhEPO) industry development. In 2022, global % sales of Recombinant Human Erythropoietin (rhEPO) went into Hospitals filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Human Erythropoietin (rhEPO) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
3SBio
Shanghai Chemo
Chengdu Diao
NCPC Genetech
Kyowa Hakko Kirin
Shandong Kexing
Ahua Pharmaceutical
Biosidus
Dragon Pharma
Segment by Type
ESRD
Cancer
HIV
Wounds and Neural Disease
Segment by Application
Hospitals
Retail Pharmacies
Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Recombinant Human Erythropoietin (rhEPO) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Human Erythropoietin (rhEPO), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Human Erythropoietin (rhEPO) industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Human Erythropoietin (rhEPO) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Human Erythropoietin (rhEPO) introduction, etc. Recombinant Human Erythropoietin (rhEPO) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Recombinant Human Erythropoietin (rhEPO) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices